MktsMarkets

Oramed Pharmaceuticals Inc.
NASDAQ: ORMPKey statistics
ORMP News
Stories mentioning ORMP from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 2,000 | |||||||
| Cost of Goods Sold | 1,987 | |||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 13.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 1,594 | 1,988 | 1,153 | 1,034 | 2,206 | 1,461 | 2,242 | 1,442 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (3,659) | (5,672) | (2,427) | (2,489) | (4,500) | (3,595) | (3,089) | (3,135) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | (100.00) | (143.00) | ||||||
| Pretax Income | 49,440 | 9,797 | 59,451 | 13,134 | (7,058) | (9,783) | (18,509) | 10,838 |
| Tax Provision | 11,130 | (212.00) | 11,062 | (126.00) | 584.00 | 1,133 | 1,634 | |
| Net Income (Loss) | 38,310 | 10,009 | 48,395 | 13,288 | (7,642) | (10,189) | (19,619) | 9,212 |
| Earnings Per Share (Basic) | 0.94 | 0.24 | 1.16 | 0.32 | (0.19) | (0.25) | (0.48) | 0.22 |
| Earnings Per Share (Diluted) | 0.91 | 0.24 | 1.13 | 0.31 | (0.19) | (0.25) | (0.48) | 0.22 |
| Weighted Average Shares Outstanding (Basic) | 40,774 | 41,403 | 41,756 | 41,743 | 41,229 | 40,850 | 40,897 | 40,960 |
| Weighted Average Shares Outstanding (Diluted) | 41,970 | 42,419 | 42,775 | 42,609 | 41,229 | 40,850 | 40,897 | 41,591 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ORMP
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is a stock listed on the Nasdaq Stock Market under the ticker symbol ORMP. It last traded at $3.86 (Nov 6, 2026, 4:00 PM ET), down 0.8% on the day. That gives Oramed Pharmaceuticals a market capitalisation of $160.6M and a price-to-earnings ratio of 0.9.
Over the past 52 weeks ORMP has traded between $2.09 and $5.47.
Net income for the quarter ended Mar 31, 2026 was $38.3M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | $38.3M |
| Dec 31, 2025 | — | $10.0M |
| Sep 30, 2025 | — | $48.4M |
| Jun 30, 2025 | — | $13.3M |
From Oramed Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…